T1	Participants 205 312	sexual function in men with lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH)
T2	Participants 690 797	372 patients were randomized to receive alfuzosin (n=186) or placebo (n=186), with 355 completing the study
T3	Participants 923 964	320 patients who completed the DAN-PSSsex
